Mike Quigley, executive director and co-lead of Immuno-Oncology (I-O) Resistance Biology, recently made a cross-country move from Lawrenceville to Redwood City – a move he’s made before. Mike’s career with Bristol-Myers Squibb started in Redwood City, where he worked for three years before heading east to be closer to family. Now, Mike is back in Redwood City to lead a translational team focused on understanding mechanisms of I-O resistance. His team, which comprises other East Coast transplants along with new hires from the Bay Area, will be working out of new state-of-the-art labs, which opened in the spring of 2018.
“Embedding our resistance team in Redwood City, which is an engine of I-O discovery, will facilitate fast, real-time decisions that can inform the science in earlier stages,” said Quigley.
Bo Barnhart, senior director of Immuno-Oncology, has also made a cross-country move to join the I-O team in Redwood City. Bo joined Bristol-Myers Squibb’s oncology discovery team in Lawrenceville after completing his post-doctoral studies at the University of Pennsylvania. After six years in Lawrenceville, he was excited by the opportunity to join a team led by Nils Lonberg and Alan Korman, pioneers in the field of I-O discovery research, and the vibrant Bay Area life science community. Ultimately, he found that while he might be 3,000 miles away from his former lab in New Jersey, the spirit of discovery and exploration spans across all R&D sites.
“One of the real strengths of Bristol-Myers Squibb is that researchers are given the freedom and support to follow a mechanism to understand the biology and how it works before we then try to apply it to drug discovery, and that’s true no matter where you are in the company,” said Barnhart.
Michael Robbins is also relocating to take on a new role, leaving behind the suburbs of Princeton, New Jersey to relocate to Bristol-Myers Squibb’s new R&D site in Cambridge, Massachusetts. In Cambridge, Michael will be joining the recently formed clinical mechanisms team in translational medicine, where he’ll focus on researching a greater mechanistic understanding of how assets work as early as possible – before late-stage human trials.
“There are a lot of unique opportunities in Cambridge, both from a research perspective and from a team perspective. As part of the growing translational medicine group, we have an exciting opportunity to deeply understand the various mechanisms of our pipeline assets, which is a critical piece of understanding why some patients do not respond to immuno-oncology,” said Robbins. ”From a workforce perspective, the Cambridge area is full of talent and partners that will continue to fuel our scientific progress. I’m really excited about the opportunities that our Cambridge presence will bring, and grateful for the opportunity to continue to grow with Bristol-Myers Squibb – across teams and geographies.”